Evidence map›Paper›PMID 17342089›Full record

ArticleBritish journal of cancer2007

Apoptosis assays with lymphoma cell lines: problems and pitfalls.

M J Mattes

Abstract read
In one paragraph

Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Cell death induction by3 Biotech · 2020
    Article
  5. Article
  6. Nicotine Prevents and Reverses Paclitaxel-Induced Mechanical Allodynia in a Mouse Model of CIPN.The Journal of pharmacology and experimental therapeutics · 2018
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

M J MattesGarden State Cancer Center at the Center for Molecular Medicine and Immunology, 520 Belleville Avenue, Belleville, NJ 07109, USA. mjmattes@gscancer.org

Funding

Targeted Therapy of B-cell MalignanciesP01CA103985 · NCI · CTR FOR MOLECULAR MEDICINE/IMMUNOLOGY · PI GOLDENBERG, DAVID M · 2005 to 2009
$7.0M
NCI NIH HHS P01 CA103985
6 · The paper itself

Abstract

Much attention has been focused on the manner in which tumour cells die after treatment with cytotoxic agents. The basic question is whether cells die via apoptosis or via direct damage from the toxic agent. Various assays have been used to make this distinction. However, we show herein that some of the widely used assays for apoptosis do not in fact distinguish between apoptosis and other forms of cell death. More specifically: (1) A sub-G1 DNA content, identified by propidium iodide staining, does not distinguish between apoptotic and necrotic cells; (2) loss of mitochondrial membrane potential does not distinguish between apoptotic and necrotic cells, unless combined with an assay for an intact cell membrane; (3) subcellular fragments that arise from dead cells or from apoptotic bodies can interfere with some assays for apoptosis such as annexin V staining, as they may be close to the size of intact cells, making it difficult to decide where to set the size threshold; (4) irradiated cells display a large increase in nonspecific Ab binding. This may be partly due to an increase in cell size, but, regardless of the cause, it can lead to a mistaken conclusion that there is an increase in a particular antigen if appropriate control reagents are not tested; and (5) experiments utilising Ab crosslinking have neglected the role of cell aggregation, which can cause multiple problems including death from mechanical stress when cells are handled. Consideration of these factors will improve our ability to determine the mode of cell death.

Indexed as

Annexin A5ApoptosisBenzimidazolesCarbocyaninesCell AggregationCell Line, TumorCollagen Type XIDNA, NeoplasmHumansJurkat CellsLymphomaMembrane Potential, MitochondrialPoly(ADP-ribose) PolymerasesPropidium5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanineAnnexin A5BenzimidazolesCarbocyaninesCOL11A2 protein, humanCollagen Type XIDNA, NeoplasmPoly(ADP-ribose) PolymerasesPropidium

Identifiers

PMID17342089
PMCPMC2360094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.